Creative Biolabs has expanded its preclinical support with tailored antibody discovery solutions for antibody-antibiotic conjugates.
SHIRLEY, NY, UNITED STATES, August 24, 2026 /EINPresswire.com/ — This updated suite specifically assists global pharmaceutical scientists and academic laboratories in navigating the early stages of AAC design against Staphylococcus aureus (S. aureus) and its methicillin-resistant strains (MRSA).
Expanding the AAC Toolkit Against Gram-Positive Pathogens
As antimicrobial resistance (AMR) remains a complex challenge in public health, researchers are increasingly exploring AACs—an innovative modality that utilizes monoclonal antibodies (mAbs) to deliver targeted antimicrobial payloads directly to bacterial infection sites. To facilitate these highly specialized development pipelines, Creative Biolabs now offers comprehensive antibody discovery for preclinical S. aureus AAC research.
Leveraging advanced isolation technologies, this service provides customized workflows spanning initial antigen design and immunization through high-throughput antibody screening. By acting as a technical extension of the client’s lab, the company helps researchers identify and optimize antibody candidates required for preclinical AAC candidates.
Technical Analysis: Addressing Specific Virulence Targets
A common technical hurdle in preclinical AAC planning is selecting an optimal surface antigen that maintains consistent expression during an active infection. To address this biological bottleneck, Creative Biolabs has introduced targeted discovery services focusing on thoroughly documented S. aureus biomarkers.
One critical focal point in the current research landscape is the iron-regulated surface determinant B (IsdB), a transport protein essential for bacterial iron scavenging. By providing specialized IsdB-targeted mAb discovery programs, the company assists investigators in developing targeting vectors that specifically recognize bacteria operating under host iron restriction, a common state during systemic infections.
Additionally, for MRSA-focused research programs, the company has established rigorous screening protocols for PBP2a-specific antibody development. Penicillin-binding protein 2a (PBP2a) is the primary structural determinant of β-lactam resistance. Supporting the discovery of antibodies against this specific target empowers researchers to explore novel conjugate formulations that aim to bypass or neutralize established bacterial defense mechanisms.
Perspectives on Early-Stage AAC Research
“The development of antibody-antibiotic conjugates presents unique bioengineering challenges, particularly regarding antigen specificity, linker chemistry, and conjugate stability in complex biological matrices,” stated the Senior Scientific Director of Antibody Development at Creative Biolabs. “By optimizing the targeting moiety for specific surface antigens like PBP 2a and IsdB, we help our clients streamline their early-stage experimental workflows and generate robust feasibility data.”
Driving Innovation in Preclinical Pipelines
Operating strictly as a contract research partner, Creative Biolabs provides the technical infrastructure required for complex assay development, affinity maturation, and conjugate analytical support. The newly updated S. aureus service matrix is designed to generate reproducible in vitro data, laying a solid foundation for clients’ subsequent in vivo efficacy evaluations.
For exploring tailored antibody discovery solutions for your AAC pipeline, please visit https://www.creative-biolabs.com/adc/.
Candy Swift
Creative Biolabs
+1 631-830-6441
marketing@creative-biolabs.com
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
